NCT04471922View on ClinicalTrials.gov

A Multiple Ascending High Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 21, 2019

Primary Completion Date

March 28, 2019

Study Completion Date

March 28, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

Anaprazole Sodium enteric-coated tablet

Multiple ascendinng dose, anaprazole 60mg QD(60mg QD group), 80mg QD(80mg QD group), 100mg QD(100mg QD group) , 7 days, fasting oral administration.

DRUG

Placebo

Multiple dose, 1 tablet QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.

DRUG

Active controlled (rabeprazole)

Multiple dose, rabeprazole 20mg QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.

Trial Locations (1)

100039

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Sihuan Pharmaceutical Holdings Group Ltd.

INDUSTRY

NCT04471922 - A Multiple Ascending High Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects | Biotech Hunter | Biotech Hunter